European Commission logo
italiano italiano
CORDIS - Risultati della ricerca dell’UE
CORDIS

DNA replication at the heart of cell fate decisions and cancer development

Descrizione del progetto

Il ruolo della replicazione del DNA sul destino cellulare

La fedele duplicazione del genoma attraverso la replicazione del DNA può essere messa in discussione da vari stress, con conseguenze disastrose per l’integrità del genoma e il destino delle cellule. Il progetto RepliFate, finanziato dal programma di azioni Marie Skłodowska-Curie, si propone di studiare i meccanismi con cui la replicazione del DNA influenza il destino delle cellule e può portare al cancro e ad altre malattie. Il progetto offrirà una formazione ai ricercatori europei e genererà conoscenze fondamentali sul processo di trasformazione maligna. L’individuazione degli attori chiave nella replicazione del DNA alimenterà gli sforzi futuri nella progettazione di trattamenti antitumorali innovativi.

Obiettivo

RepliFate is doctoral network designed to train the next generation of European researchers in the field of DNA replication, cell fate and cancer. We have designed an innovative training program that aims at providing interdisciplinary and intersectoral formation for the fellows. We base the network in inclusion, creativity and communication as the base to train the researchers in all aspects of scientific activity.

RepliFate will investigate the mechanisms through which changes in DNA replication influence cell identity, respond to different kinds of stress, and prevent malignant transformation. We will put DNA replication at the center stage as the driver of these processes and not a mere bystander, using recent technological to better understand the role of DNA replication as a determinant of cell fate and cancer. RepliFate links academia with industry and society and will provide new opportunities for innovation in one of the main societal challenges in human health, cancer. The scientific roots of RepliFate are set on the Horizon Europe Mission Cancer objectives Understand and Optimise. We will pave the way for the development of innovative cancer treatments exploring the links between DNA replication and cell fate, the immune response and unscheduled cell proliferation.

RepliFate is composed by 10 European beneficiaries (9 from academia and 1 from industry) along with 2 Swiss associated partners (with their own funding from the Swiss government), 4 companies, 1 news agency and 2 non-profit organizations as associated partners from 8 different countries. Putting the focus on the fellows, we have combined our expertise to create an outstanding training program with the objective to generate leaders in the field with independent and out-of-the-box views to drive the knowledge of basic science to applications that will improve the resilience of the European society by positively impacting on our response to the huge health challenge constituted by Cancer.

Coordinatore

AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS
Contribution nette de l'UE
€ 755 913,60
Indirizzo
CALLE SERRANO 117
28006 Madrid
Spagna

Mostra sulla mappa

Regione
Comunidad de Madrid Comunidad de Madrid Madrid
Tipo di attività
Research Organisations
Collegamenti
Costo totale
Nessun dato

Partecipanti (7)

Partner (13)